Agilent Technologies, Inc. logo
Agilent Technologies, Inc. (A)
Compare

Agilent Technologies, Inc. (A) EV/Assets Ratio: 2.98x

Is Agilent Technologies, Inc.’s EV/Assets ratio high or low?

Agilent Technologies, Inc.'s EV/Assets ratio of 2.98x is 20% below its 5-year average of 3.71x, near the low end of its 5-year range (2.55x–5.37x).

The EV/Assets ratio for Agilent Technologies, Inc. (A) is 2.98x as of Wednesday, June 10, 2026. It is below its 12-month average by 2.54% (3.06x).

A EV/Assets Ratio Chart

A EV/Assets Ratio
2.98x-0.33% 1Y
Zoom

A Average EV/Assets Ratio Chart

A Current vs Average EV/Assets Ratio Chart

A EV/Assets Ratio Metrics

EV/ASSETS RATIO

2.98x

EV/ASSETS RATIO AVG TTM

3.06x

EV/ASSETS RATIO AVG 3Y

3.38x

EV/ASSETS RATIO AVG 5Y

3.71x

EV/ASSETS RATIO AVG 10Y

3.22x

EV/ASSETS RATIO AVG 15Y

2.57x

EV/ASSETS RATIO AVG 20Y

2.21x

CURRENT VS TTM AVG

-2.54%

CURRENT VS 3Y AVG

-11.89%

CURRENT VS 5Y AVG

-19.72%

CURRENT VS 10Y AVG

-7.32%

CURRENT VS 15Y AVG

+16.14%

CURRENT VS 20Y AVG

+34.70%

A Competitors' EV/Assets Ratio

NAMEMARKET CAPEV/ASSETS RATIOTTM3Y5Y
Agilent Technologies, Inc. (A)2.98x3.06x3.38x3.71x
Zoetis Inc. (ZTS)$34.20B2.75x4.26x5.44x5.84x
Centene Corporation (CNC)$31.94B0.33x0.25x0.39x0.51x
IQVIA Holdings Inc. (IQV)$30.60B1.05x1.56x1.81x1.98x
Humana Inc. (HUM)$43.78B0.96x0.75x0.88x1.10x
IDEXX Laboratories, Inc. (IDXX)$44.47B13.69x15.32x13.69x15.18x
DexCom, Inc. (DXCM)$29.24B4.53x4.23x5.88x7.47x
Biogen Inc. (BIIB)$29.00B1.10x0.95x1.19x1.43x
Veeva Systems Inc. (VEEV)$27.37B2.85x4.64x5.33x7.00x
Waters Corporation (WAT)$23.83B1.43x4.12x4.55x5.47x

Agilent Technologies, Inc. EV/Assets Ratio Formula & Definition

EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Agilent Technologies, Inc. EV/Assets Ratio FAQ

What is the EV/Assets ratio for Agilent Technologies, Inc. (A)?
The EV/Assets ratio for A stock is 2.98x.
Is Agilent Technologies, Inc.'s EV/Assets ratio high or low?
Agilent Technologies, Inc.'s EV/Assets ratio of 2.98x is 20% below its 5-year average of 3.71x, near the low end of its 5-year range (2.55x–5.37x).
What is the TTM average EV/Assets ratio for Agilent Technologies, Inc. (A)?
The TTM average EV/Assets ratio for A stock is 3.06x.
What is the 3Y average EV/Assets ratio for Agilent Technologies, Inc. (A)?
The 3Y average EV/Assets ratio for A stock is 3.38x.
What is the 5Y average EV/Assets ratio for Agilent Technologies, Inc. (A)?
The 5Y average EV/Assets ratio for A stock is 3.71x.
What is the 10Y average EV/Assets ratio for Agilent Technologies, Inc. (A)?
The 10Y average EV/Assets ratio for A stock is 3.22x.
What is the 15Y average EV/Assets ratio for Agilent Technologies, Inc. (A)?
The 15Y average EV/Assets ratio for A stock is 2.57x.
What is the 20Y average EV/Assets ratio for Agilent Technologies, Inc. (A)?
The 20Y average EV/Assets ratio for A stock is 2.21x.

Agilent Technologies, Inc. EV/Assets Ratio History

DATEEV/ASSETS RATIO
2026-06-102.98x
2026-06-093.06x
2026-06-083.00x
2026-06-053.06x
2026-06-043.13x
2026-06-033.11x
2026-06-023.05x
2026-06-013.07x
2026-05-293.13x
2026-05-283.13x
2026-05-272.69x
2026-05-262.68x
2026-05-222.67x
2026-05-212.67x
2026-05-202.65x
2026-05-192.58x
2026-05-182.61x
2026-05-152.60x
2026-05-142.63x
2026-05-132.62x
2026-05-122.63x
2026-05-112.60x
2026-05-082.69x
2026-05-072.75x
2026-05-062.73x
2026-05-052.73x
2026-05-042.61x
2026-05-012.66x
2026-04-302.69x
2026-04-292.59x
2026-04-282.67x
2026-04-272.69x
2026-04-242.69x
2026-04-232.66x
2026-04-222.79x
2026-04-212.83x
2026-04-202.81x
2026-04-172.83x
2026-04-162.75x
2026-04-152.78x
2026-04-142.79x
2026-04-132.73x
2026-04-102.67x
2026-04-092.68x
2026-04-082.72x
2026-04-072.65x
2026-04-062.67x
2026-04-022.68x
2026-04-012.66x
2026-03-312.65x
2026-03-302.61x
2026-03-272.57x
2026-03-262.64x
2026-03-252.63x
2026-03-242.66x
2026-03-232.61x
2026-03-202.59x
2026-03-192.60x
2026-03-182.60x
2026-03-172.62x
2026-03-162.60x
2026-03-132.60x
2026-03-122.60x
2026-03-112.68x
2026-03-102.68x
2026-03-092.71x
2026-03-062.68x
2026-03-052.74x
2026-03-042.80x
2026-03-032.76x
2026-03-022.76x
2026-02-272.83x
2026-02-262.82x
2026-02-252.91x
2026-02-242.90x
2026-02-232.89x
2026-02-202.87x
2026-02-192.94x
2026-02-182.96x
2026-02-172.89x
2026-02-132.93x
2026-02-122.91x
2026-02-113.00x
2026-02-103.00x
2026-02-092.97x
2026-02-063.01x
2026-02-053.02x
2026-02-043.09x
2026-02-033.07x
2026-02-023.14x
2026-01-303.11x
2026-01-293.10x
2026-01-283.11x
2026-01-273.16x
2026-01-263.15x
2026-01-233.14x
2026-01-223.22x
2026-01-213.24x
2026-01-203.15x
2026-01-163.24x
2026-01-153.35x
2026-01-143.38x
2026-01-133.39x
2026-01-123.43x
2026-01-093.44x
2026-01-083.38x
2026-01-073.42x
2026-01-063.42x
2026-01-053.31x
2026-01-023.20x
2025-12-313.16x
2025-12-303.19x
2025-12-293.20x
2025-12-263.21x
2025-12-243.21x
2025-12-233.21x
2025-12-223.21x
2025-12-193.19x
2025-12-183.34x
2025-12-173.34x
2025-12-163.40x
2025-12-153.43x
2025-12-123.41x
2025-12-113.48x
2025-12-103.50x
2025-12-093.43x
2025-12-083.47x
2025-12-053.54x
2025-12-043.61x
2025-12-033.63x
2025-12-023.62x
2025-12-013.65x
2025-11-283.73x
2025-11-263.75x
2025-11-253.82x
2025-11-243.73x
2025-11-213.68x
2025-11-203.53x
2025-11-193.52x
2025-11-183.51x
2025-11-173.52x
2025-11-143.58x
2025-11-133.58x
2025-11-123.69x
2025-11-113.64x
2025-11-103.57x
2025-11-073.57x
2025-11-063.59x
2025-11-053.57x
2025-11-043.56x
2025-11-033.53x
2025-10-313.57x
2025-10-303.50x
2025-10-293.49x
2025-10-283.55x
2025-10-273.57x
2025-10-243.60x
2025-10-233.59x
2025-10-223.55x
2025-10-213.55x
2025-10-203.49x
2025-10-173.46x
2025-10-163.44x
2025-10-153.41x
2025-10-143.37x
2025-10-133.38x
2025-10-103.34x
2025-10-093.42x
2025-10-083.44x
2025-10-073.38x
2025-10-063.45x
2025-10-033.46x
2025-10-023.39x
2025-10-013.38x
2025-09-303.15x
2025-09-293.04x
2025-09-263.03x
2025-09-252.99x
2025-09-243.05x
2025-09-233.09x
2025-09-223.10x
2025-09-193.10x
2025-09-183.13x
2025-09-173.11x
2025-09-163.12x
2025-09-153.08x
2025-09-123.03x
2025-09-113.11x
2025-09-103.05x
2025-09-093.10x
2025-09-083.14x
2025-09-053.15x
2025-09-043.15x
2025-09-033.07x
2025-09-023.07x
2025-08-293.08x
2025-08-283.09x
2025-08-272.95x
2025-08-262.94x
2025-08-252.96x
2025-08-223.02x
2025-08-212.91x
2025-08-202.96x
2025-08-192.98x
2025-08-182.93x
2025-08-152.96x
2025-08-142.95x
2025-08-132.99x
2025-08-122.92x
2025-08-112.84x
2025-08-082.85x
2025-08-072.84x
2025-08-062.82x
2025-08-052.86x
2025-08-042.86x
2025-08-012.83x
2025-07-312.86x
2025-07-302.93x
2025-07-292.97x
2025-07-282.97x
2025-07-252.98x
2025-07-242.99x
2025-07-232.97x
2025-07-222.89x
2025-07-212.79x
2025-07-182.84x
2025-07-172.89x
2025-07-162.82x
2025-07-152.81x
2025-07-142.98x
2025-07-113.06x
2025-07-103.08x
2025-07-093.01x
2025-07-083.00x
2025-07-072.96x
2025-07-033.01x
2025-07-022.99x
2025-07-012.99x
2025-06-302.93x
2025-06-272.96x
2025-06-262.96x
2025-06-252.95x
2025-06-242.92x
2025-06-232.89x
2025-06-202.87x
2025-06-182.87x
2025-06-172.89x
2025-06-162.96x
2025-06-132.91x
2025-06-122.95x
2025-06-112.97x
2025-06-102.99x
2025-06-092.90x
2025-06-062.88x
2025-06-052.84x
2025-06-042.86x
2025-06-032.81x
2025-06-022.77x
2025-05-302.79x
2025-05-292.89x

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Santa Clara, CA
17,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Padraig McDonnell